| Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation in Myelodysplastic Syndromes: Systematic Review and Meta-analysis |
|
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation |
Myelodysplastic Syndromes (MDS) |
| Why Hurry Up and Wait? Transplantation in Lower-Risk Myelodysplastic Syndromes |
|
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation |
Myelodysplastic Syndromes (MDS) |
| A Case Series of Post-Transplantation Cyclophosphamide in Unrelated Donor Hematopoietic Cell Transplantation for Aplastic Anemia |
|
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation |
Aplastic Anemia |
| Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate, but not High Disease Risk Index: A CIBMTR Study: Superior DFS with MAC comp |
|
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Impact of CD34 Cell Dose and Conditioning Regimen on Outcomes after Haploidentical Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Relapsed/Refractory Severe Aplastic Anemia |
|
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation |
Aplastic Anemia |
| The case for upfront HLA-matched unrelated donor HCT as a curative option for adult acquired severe aplastic anemia: Upfront MUD HCT for adult severe aplastic anemia |
|
Biology of Blood and Marrow Transplantation: Journal of the American Society of Blood and Marrow Transplantation |
Aplastic Anemia |
| Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM) |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Efficacy and Safety of Venetoclax Plus Azacitidine for Patients With Treatment-Naive High-Risk Myelodysplastic Syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
